Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech hopes to differentiate its candidate from recent obesity drug failures with better risk-to-benefit ratio, serving severely obese patients.